Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sIPV vaccine + DTaP vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
sIPV vaccine + DTaP vaccine refers to the concomitant administration of Sinovac Biotech's Sabin-strain inactivated poliovirus vaccine (sIPV) and a diphtheria-tetanus-acellular pertussis (DTaP) vaccine. The sIPV component is a trivalent inactivated vaccine produced from Sabin poliovirus types 1, 2, and 3 grown on Vero cells, while the DTaP vaccine provides protection against diphtheria, tetanus, and pertussis. This co-administration strategy is intended for the primary and booster immunization of infants and children starting from 2 months of age. Clinical studies, including Phase 4 trials, have evaluated the safety and immunogenicity of this simultaneous vaccination approach, demonstrating that it is well-tolerated and provides effective immune responses against all targeted pathogens without significant interference between the components.
- Other names
- sIPV and DTaP co-administrationSabin inactivated poliovirus vaccine and diphtheria-tetanus-acellular pertussis vaccine
02
Targets
PRN (Pertactin)Poliovirus type 3 D-antigenTT (Tetanus toxoid)FHA (Filamentous hemagglutinin)Poliovirus type 1 D-antigen
Beyond the preview
Go deeper on sIPV vaccine + DTaP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sIPV vaccine + DTaP vaccine.